cagrilintide semaglutide combination trial weight loss New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Semaglutide and cagrilintide have each
Description
However, the reality is more cautious
Nutrients 14 , 2169 (2022)
References Viana CM, Freire D, Abrantes P, Rocha J, Pereira P
All products sold by Regen Peptides are intended for laboratory research only and are not for human consumption.
However, when paired with GLP-1 in dual agonists like tirzepatide, the combination works synergistically to suppress appetite and increase energy expenditure
In blood pressure studies, the peptide did not affect basal blood pressure but counteracted both L-NAME-induced hypertension and L-arginine-induced hypotension
